Shots:

• HLX04 is a biosimilar that binds to vascular endothelial growth factor (VEGF) for inhibiting angiogenesis where VEGF acts for promoting growth of blood vessels can inhibit tumor angiogenesis further preventing tumor growth or metastasis. The biosimilar was developed under Chinese biosimilar guideline
• The P-III HLX04-mCRC03 trial involves assessing of HLX04 (biosimilar- bevacizumab) or Avastin (bevacizumab) in combination with oxaliplatin and fluoropyrimidine-based CT (XELOX or mFOLFOX6) for 1L patients with mCRC and showed bioequivalent to the Avastin in terms of PK and AEs
• The product has also shown bio-similarity in product quality- pharmacology- PK- PD- toxicology and immunogenicity in analytical studies- preclinical studies and P-I clinical study- Presented at Chinese Society of Clinical Oncology

Click here to read full press release/ article | Ref: Henlius | Image: Henlius